Effect of BN 52063, a specific PAF-acether antagonist, on bronchial provocation test to allergens in asthmatic patients. A preliminary study.
Platelet Activating Factor, PAF-acether, elicits acute and more prolonged inflammatory responses in both experimental animals and man, and is recognised as a possible mediator of asthma. The effect of a specific PAF-acether antagonist, BN 52063, on the early asthmatic response to inhaled allergen was assessed in a randomised, double-blind, crossover study in eight atopic asthmatics, who received three days treatment with BN 52063 or placebo, separated by a one week washout. On the third day of treatment, subjects were challenged with nebulised house dust mite or pollen allergen. BN 52063 significantly antagonised early bronchoconstriction and showed a tendency to inhibit residual bronchial hyperreactivity, assessed six hours after allergen challenge by a provocation test to acetylcholine. No side effects were reported during active treatment. This is the first study in man demonstrating the efficacy of a specific PAF-acether antagonist on the immediate response to inhaled allergen challenge in asthmatics. The findings support the possible role of specific PAF-acether antagonists in the treatment of asthma.
Ipsen International Ltd, London, England.
P
P
Guinot
C
C
Brambilla
J
J
Duchier
P
P
Braquet
B
B
Bonvoisin
A
A
Cournot
D000109:Acetylcholine; D000328:Adult; D000403:Airway Resistance / Q000187:drug effects; D000485:Allergens; D001249:Asthma / Q000503:physiopathology*; D001985:Bronchial Provocation Tests; D001986:Bronchial Spasm / Q000503:physiopathology; D005260:Female; D006801:Humans; D007783:Lactones; D008297:Male; D010936:Plant Extracts / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*
D000485:Allergens; D007783:Lactones; D010936:Plant Extracts; D010972:Platelet Activating Factor; C050422:BN 52063; D000109:Acetylcholine